Adult ADHD Evaluation: What Patients Should Expect Before Medication
Written by Dr. Oswaldo Romero, PMHNP-BC
ADHD is having a moment. Social media is full of relatable content about forgetfulness, procrastination, and difficulty focusing; and for many adults, these posts are the first time they have ever considered that their lifelong struggles might have a name. The result has been a surge in adults seeking evaluation for attention-deficit/hyperactivity disorder, many for the first time.
That growing awareness is a good thing. ADHD is a real, well-established neurodevelopmental disorder that affects an estimated 2.5% to 3.1% of adults worldwide, and up to 14.6% of U.S. adults may meet diagnostic criteria. It is underdiagnosed, undertreated, and associated with significant impairment in work, relationships, and daily functioning. Many adults have spent decades struggling without understanding why.
But awareness is not the same as diagnosis. And diagnosis is not the same as a prescription. A responsible ADHD evaluation is a clinical process; it is one that takes time, thoroughness, and professional judgment. This blog explains what that process looks like, why each step matters, and what patients should expect before any medication is discussed.
Why a Thorough Evaluation Matters
ADHD cannot be diagnosed with a single questionnaire, a five-minute conversation, or a social media checklist.
ADHD shares symptoms with a long list of other conditions. Difficulty concentrating, restlessness, forgetfulness, emotional reactivity, and disorganization can all be caused or worsened by depression, anxiety, bipolar disorder, PTSD, sleep disorders, thyroid dysfunction, substance use, personality disorders, and even chronic stress. Emotional dysregulation, once considered a secondary feature, is now recognized as common in ADHD, but it overlaps substantially with symptoms of mood and personality disorders.
A review in American Family Physician emphasizes that because other mental disorders commonly co-occur with ADHD, it is important to screen patients for multiple mental health issues during the evaluation. The DSM-5-TR Self-Rated Level 1 Cross-Cutting Symptom Measure is a 23-item tool that screens for depression, anxiety, mania, somatization, self-harm, psychosis, sleep issues, memory problems, personality disorders, and substance misuse — all of which can mimic or coexist with ADHD.
If a provider diagnoses ADHD without ruling out these other possibilities, the patient may end up on the wrong medication for the wrong condition.
Step 1: The Comprehensive Clinical Interview
The foundation of an ADHD evaluation is a detailed clinical interview. This is not a casual conversation. It is a structured exploration of the patient's history, symptoms, and functioning across multiple domains.
The interview typically covers:
- Current symptoms: what specific difficulties the patient is experiencing with attention, organization, impulsivity, restlessness, and emotional regulation, and how these affect daily life
- Childhood history: ADHD is a neurodevelopmental disorder, which means symptoms must have been present before age 12. The DSM-5-TR requires evidence that several inattentive or hyperactive-impulsive symptoms were present during childhood, even if they were not recognized or diagnosed at the time. For adults who were never evaluated as children, this often requires careful retrospective questioning about school performance, behavior, and functioning
- Functional impairment: symptoms must cause clinically significant impairment in at least two settings, such as work, home, or social relationships. A person who is occasionally forgetful but functions well does not meet criteria. Conversely, some people with ADHD appear high-performing in one setting but spend enormous effort maintaining that performance or have reduced functioning in other areas
- Psychiatric history: prior diagnoses, treatments, hospitalizations, and medication trials
- Medical history: conditions like thyroid disease, sleep apnea, traumatic brain injury, and chronic fatigue can produce ADHD-like symptoms and must be considered
- Substance use history: drugs and alcohol can cause or worsen virtually every ADHD symptom, and a detailed substance use history is essential
- Family history: ADHD is highly heritable. A family history of ADHD in a first-degree relative significantly increases the likelihood of the diagnosis in an adult
The clinical interview is the single most important component of the evaluation. No screening tool or questionnaire can replace it.
Step 2: Validated Screening and Diagnostic Tools
After the clinical interview, standardized rating scales are used to quantify symptoms and assess their severity. These tools are not diagnostic on their own — diagnostic self-report tests tend to lack specificity and result in a high false-positive rate if used alone — but they provide structured, validated data that complement the clinical interview.
Commonly used tools include:
- The Adult ADHD Self-Report Scale (ASRS): an 18-item questionnaire developed in conjunction with the World Health Organization. The DSM-5 version of the ASRS correctly classified nearly all people who met diagnostic criteria for ADHD in clinical interviews, with sensitivity above 90%. It is widely used as an initial screening tool
- The Conners Adult ADHD Rating Scales (CAARS): available in both self-report and observer-report versions, with embedded validity indicators that help detect exaggerated or inconsistent responding. The fourth edition has the highest specificity among available tools
- The Weiss Functional Impairment Rating Scale: assesses functional impairment across seven domains including work, school, social life, and self-concept
- The Wender Utah Rating Scale: a retrospective measure of childhood ADHD symptoms, useful for establishing the developmental history required by DSM-5-TR
A three-part diagnostic approach is recommended: (1) confirm that symptoms were present before age 12, (2) complete validated self-report and observer screening measures, and (3) verify that DSM-5-TR diagnostic criteria are met, including the presence of symptoms in two or more settings with a major impact on function.
Step 3: Collateral Information
One of the most important, and most overlooked, components of an adult ADHD evaluation is collateral information. Adults with ADHD often have poor insight into their own symptoms and may underestimate the severity of their impairments. Self-report alone is less predictive than reports from others regarding problems with employment, relationships, and social functioning.
Collateral information can include:
- Observer reports from a spouse, partner, parent, or close friend who has known the patient over time
- Childhood records such as report cards, school transcripts, or prior psychological evaluations
- Work performance evaluations or documentation of job difficulties
- Prior medical or psychiatric records
Free, research-supported observer forms are available, including the Current Behaviour Scale – Partner Report and the retrospective Childhood Behaviour Scale – Parent Report. These provide structured input from someone who knows the patient well and can offer a perspective the patient may not have about their own behavior.
Collateral information is not always available — and its absence does not automatically rule out ADHD. But when it is available, it significantly strengthens the diagnostic process.
Step 4: Ruling Out Other Conditions
Before an ADHD diagnosis can be made, the provider must systematically consider and rule out other conditions that could explain the symptoms. This is called the differential diagnosis, and it is one of the most critical steps in the evaluation.
Conditions that can mimic ADHD in adults include:
- Major depressive disorder: poor concentration, low motivation, and cognitive slowing are hallmark symptoms of depression
- Generalized anxiety disorder: difficulty concentrating, restlessness, and irritability overlap significantly with ADHD
- Bipolar disorder: impulsivity, distractibility, and hyperactivity during manic or hypomanic episodes can look identical to ADHD
- Post-traumatic stress disorder: difficulty concentrating, hypervigilance, and emotional dysregulation are common in PTSD
- Sleep disorders: chronic sleep deprivation from any cause (insomnia, sleep apnea, restless legs syndrome) produces inattention, impulsivity, and cognitive impairment that closely resembles ADHD
- Thyroid dysfunction: both hypothyroidism and hyperthyroidism can affect attention, energy, and mood
- Substance use disorders: stimulant, cannabis, and alcohol use can all produce or worsen attention and executive function difficulties
- Personality disorders: particularly borderline personality disorder, which shares features of emotional dysregulation and impulsivity with ADHD
- Traumatic brain injury: even mild TBI can produce lasting attention and executive function deficits
The key distinguishing factor for ADHD is that symptoms must have been present since childhood. Conditions like depression, anxiety, and sleep disorders can cause ADHD-like symptoms, but these diagnoses can often be differentiated by confirming that attention and impulsivity problems were present before age 12 — before the onset of the other condition.
It is also important to recognize that ADHD frequently co-occurs with other psychiatric conditions. Having depression or anxiety does not rule out ADHD — but it does mean both conditions need to be identified and addressed.
Step 5: Medical Screening
A medical history and, in some cases, basic laboratory testing help rule out medical conditions that could be causing or contributing to attention difficulties. This may include:
- Thyroid function testing (TSH) — to rule out thyroid disease
- Complete blood count — to rule out anemia
- Basic metabolic panel — to assess overall metabolic health
- Urine drug screen — particularly when substance use is a concern
Before starting any ADHD medication, especially stimulants, a cardiovascular assessment is recommended. This includes measuring baseline blood pressure and heart rate. Stimulant medications can increase resting heart rate by approximately 5 to 6 beats per minute and blood pressure by 1 to 2 mmHg. While a large retrospective cohort study found no increased risk of serious cardiovascular events among young or middle-aged adults using stimulants, the FDA recommends that stimulants should not be used in patients with serious heart problems or for whom increased blood pressure or heart rate would be problematic.
An electrocardiogram (ECG) is not routinely required for all patients but may be recommended based on the patient's symptoms, medical conditions, and personal or family cardiovascular history. The decision to obtain an ECG should be at the treating clinician's discretion.
Stimulants are contraindicated in patients with uncontrolled hypertension, angina, a history of myocardial infarction, arrhythmias, significant heart valve disease, or cardiomyopathy.
When Neuropsychological Testing May Be Needed
ADHD is a clinical diagnosis and does not require neuropsychological testing in most cases. A comprehensive combination of a clinical evaluation, screening tools, diagnostic testing, and collateral information is often sufficient to make an accurate diagnosis.
However, neuropsychological testing may be valuable in specific situations:
- When collateral information such as childhood history and observer reports is lacking
- When malingering is suspected — particularly relevant given that stimulant medications are Schedule II controlled substances with potential for misuse
- When confounding comorbid mental illness makes it difficult to determine whether ADHD is present
- When learning disabilities or other focal cognitive problems may be contributing to the patient's difficulties
Neuropsychological testing incorporates symptom validity testing and performance measures — including working memory, sustained attention, reaction time, and response time variability — and can assist with diagnosis when combined with self-report and collateral information. Research has shown that a combined approach using self and informant symptom ratings, positive family history, and reaction time variability measures correctly classified 87% of cases.
The financial burden of neuropsychological testing should be a consideration. Full testing can take three to five hours and cost several thousand dollars. For the majority of patients, a thorough clinical evaluation can reach an accurate diagnosis without it.
Why This Process Cannot Be Rushed
There is a reason responsible providers do not diagnose ADHD and prescribe stimulants in a single visit. The stakes are too high in both directions.
Underdiagnosis means that adults who genuinely have ADHD continue to struggle without effective treatment. Research shows that approximately 70% of adults with ADHD have immediate improvement in attentiveness and reduced distractibility when treated with stimulant medications, with moderate to large effect sizes. Denying that treatment to someone who needs it is a disservice.
But overdiagnosis carries its own risks. Stimulant medications are Schedule II controlled substances with a high potential for misuse. In 2021, more than 3.4 million adults in the United States misused prescription stimulants, and an estimated 20% of those who misuse stimulants obtained prescriptions by presenting to clinicians with exaggerated or fabricated symptoms. Prescribing stimulants to someone who does not have ADHD, or who has a co-occurring substance use disorder that has not been identified, can cause harm.
A thorough evaluation protects the patient in both scenarios. It ensures that those who have ADHD receive the right diagnosis and the right treatment, and it ensures that those who do not have ADHD are not exposed to unnecessary medication risks while their actual condition goes unaddressed.
What Happens After the Evaluation
If the evaluation confirms an ADHD diagnosis, the next step is a collaborative discussion about treatment options. Medication is one component — but it is not the only one.
Treatment for adult ADHD may include:
- Stimulant medications (amphetamine or methylphenidate formulations) as first-line pharmacotherapy, with approximately 70% of adults showing a favorable response
- Nonstimulant medications such as atomoxetine, viloxazine, or bupropion for patients who cannot take stimulants or who have co-occurring anxiety or depression
- Cognitive behavioral therapy (CBT), which has evidence supporting its use in adults with ADHD, particularly when combined with medication
- Organizational strategies, coaching, and psychoeducation to address the functional impairments that medication alone may not fully resolve
If the evaluation does not confirm ADHD, that is also a valuable outcome. It may reveal a different condition (depression, anxiety, a sleep disorder, or something else entirely) that can be treated more appropriately. Or it may identify that the patient's difficulties are real but do not meet the threshold for a clinical diagnosis, in which case CBT for cognitive concerns or psychoeducational counseling may be recommended.
The Bottom Line
An ADHD evaluation is not a formality standing between a patient and a prescription. It is a clinical process designed to get the diagnosis right, because getting the diagnosis right is the only way to get the treatment right.
For adults who have spent years wondering why things feel harder than they should, a thorough evaluation can be the beginning of understanding. And for those whose difficulties turn out to have a different cause, the evaluation is equally valuable — because it points toward the treatment that will actually help.
The goal is not to make the process difficult. The goal is to make it accurate. And accuracy is what every patient deserves.
References
Attention-Deficit/Hyperactivity Disorder in Adults. Olagunju AE, Ghoddusi F. American Family Physician. 2024;110(2):157-166.
Prevalence of Attention Deficit Hyperactivity Disorder in Adults: Umbrella Review of Evidence Generated Across the Globe. Ayano G, Tsegay L, Gizachew Y, et al. Psychiatry Research. 2023;328:115449. doi:10.1016/j.psychres.2023.115449.
Attention-Deficit/Hyperactivity Disorder (ADHD) in Adults: Evidence Base, Uncertainties and Controversies. Cortese S, Bellgrove MA, Brikell I, et al. World Psychiatry : Official Journal of the World Psychiatric Association (WPA). 2025;24(3):347-371. doi:10.1002/wps.21374.
Adult Attention Deficit–Hyperactivity Disorder. Volkow ND, Swanson JM. The New England Journal of Medicine. 2013;369(20):1935-44. doi:10.1056/NEJMcp1212625.
The World Health Organization Adult Attention-Deficit/Hyperactivity Disorder Self-Report Screening Scale for DSM-5. Ustun B, Adler LA, Rudin C, et al. JAMA Psychiatry. 2017;74(5):520-527. doi:10.1001/jamapsychiatry.2017.0298.
Do I Have ADHD? Diagnosis of ADHD in Adulthood and Its Mimics in the Neurology Clinic. Mierau SB. Neurology. Clinical Practice. 2025;15(1):e200433. doi:10.1212/CPJ.0000000000200433.
The Role of Neurocognitive Tests in the Assessment of Adult Attention-Deficit/Hyperactivity Disorder. Nikolas MA, Marshall P, Hoelzle JB. Psychological Assessment. 2019;31(5):685-698. doi:10.1037/pas0000688.
Attention Deficit Hyperactivity Disorder. Thapar A, Cooper M. Lancet (London, England). 2016;387(10024):1240-50. doi:10.1016/S0140-6736(15)00238-X.
Pharmacologic Treatment of Attention Deficit–Hyperactivity Disorder. Cortese S. The New England Journal of Medicine. 2020;383(11):1050-1056. doi:10.1056/NEJMra1917069.
Occurrence of Psychosis and Bipolar Disorder in Individuals With Attention-Deficit/Hyperactivity Disorder Treated With Stimulants. Salazar de Pablo G, Aymerich C, Chart-Pascual JP, et al. JAMA Psychiatry. 2025;82(11):1103-1112. doi:10.1001/jamapsychiatry.2025.2311.
Prevalence and Incidence of Attention Deficit/Hyperactivity Disorder in Denmark. A National Register‐Based Open Cohort Study. Grøntved S, Hald K, Mohr-Jensen C, et al. Acta Psychiatrica Scandinavica. 2025;152(1):27-38. doi:10.1111/acps.13804.
Evaluation of the Persistence, Remission, and Emergence of Attention-Deficit/Hyperactivity Disorder in Young Adulthood. Agnew-Blais JC, Polanczyk GV, Danese A, et al. JAMA Psychiatry. 2016;73(7):713-20. doi:10.1001/jamapsychiatry.2016.0465.